Skip to main
LUNG
LUNG logo

Pulmonx (LUNG) Stock Forecast & Price Target

Pulmonx (LUNG) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 10%
Hold 30%
Sell 10%
Strong Sell 0%

Bulls say

Pulmonx Corp experienced a notable increase in total revenue for the full year 2024, reaching $83.8 million, representing a 22% growth from the previous year, with domestic revenue rising by 23% and international revenue increasing by 20%. The company's innovative solutions, including the Zephyr Endobronchial Valve and the Chartis Pulmonary Assessment System, are enhanced by improved reimbursement coverage and advancements in patient selection technologies, which contribute to a broader market potential and adoption. Additionally, the consistent long-term benefits demonstrated by Pulmonx's treatments strengthen physician confidence and support the company's expanding market penetration, particularly in the United States.

Bears say

Pulmonx Corp reported a quarterly gross profit of $17.6 million, resulting in a gross margin decrease to 74%, reflecting slight erosion compared to the previous quarter. The company's cash position declined from $107.8 million to $101.5 million over three months, suggesting potential liquidity concerns that could affect operational flexibility. Additionally, as a small-cap company operating in a high-risk medical technology sector, Pulmonx faces significant volatility, which could deter risk-averse investors amid ongoing challenges in addressing the needs of the growing COPD patient population.

Pulmonx (LUNG) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 10% recommend Buy, 30% suggest Holding, 10% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pulmonx (LUNG) Forecast

Analysts have given Pulmonx (LUNG) a Buy based on their latest research and market trends.

According to 10 analysts, Pulmonx (LUNG) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pulmonx (LUNG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.